Skip to content

iLink® Patient Savings Program

Section

Enroll in iLink® Patient Savings Program Eligible commercially insured patients may get up to $600 per eye towards out-of-pocket expense.*

Savings Program Eligibility Requirements:

  1. Have commercial insurance coverage
  2. Live in the United States, including US Territories
  3. Receive the iLink cross-linking procedure as prescribed by a US iLink trained physician in alignment with the iLink FDA-approved indications
  4. Have an out-of-pocket responsibility for Photrexa® drug formulations [Photrexa® Viscous (riboflavin 5′-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5′-phosphate ophthalmic solution)] identified on the insurance plan’s remittance or Explanation of Benefits*
  5. Have the iLink cross-linking procedure on or before December 31, 2025 (Note that the program application and Explanation of Benefits must be submitted within 180 days of the treatment date)
  6. Have the Explanation of Benefits from your iLink procedure available from your insurance plan. It is required to complete an application for each eye treated.

Note: You need your Explanation of Benefits (EOB) from your insurance company to submit this application.

Eligibility criteria apply. Offer valid only for commercially insured patients with a plan covering the iLink cross-linking procedure; patient out-of-pocket expense will vary. This offer applies to the Photrexa® drug formulations [Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution)] used in the iLink cross-linking procedure only and does not apply to costs for any other medication, procedure, or diagnostic service provided in conjunction or supportive to the iLink treatment. Offer not valid for patients receiving reimbursement from Medicare, Medicaid, or any other federal, state, or government-funded healthcare program.

Do you have questions about this program?

Call 1-833-855-3031 or email [email protected].

Terms & Conditions

Eligibility Check

We’re sorry. You do not appear to be eligible for the iLink Patient Savings Program according to the requirements listed below.

If you believe you are eligible or incorrect information was entered, complete the application form again. You can also call for help at 1-833-855-3031 or email [email protected].

Savings Program Eligibility Requirements:

  • Have commercial insurance coverage
  • Live in the United States, including US Territories
  • Receive the iLink cross-linking procedure as prescribed by a US iLink-trained physician in alignment with the iLink FDA-approved indication
  • Have an out-of-pocket responsibility for Photrexa® drug formulations [Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution)] identified on the insurance plan’s remittance or Explanation of Benefits
  • Have the iLink cross-linking procedure on or before December 31, 2025
  • Submit program application and Explanation of Benefits within 180 days of the treatment date

Please continue to next section to upload the required Explanation of Benefits (EOB)

Thank You!

Thank you for submitting your application. We have received your information. Please allow 6-8 weeks for processing. If you have additional questions, contact Glaukos Patient Services (GPS) at 1-833-855-3031 or email [email protected].
Find a Doctor

Important Safety Information

Ulcerative keratitis, a potentially serious eye infection, can occur. Your doctor should monitor defects in the outermost corneal layer of the eye for resolution.

The most common ocular side effect is haze. Other ocular side effects include inflammation, fine white lines, dry eye, disruption of surface cells, eye pain, light sensitivity, reduced sharpness of vision, and blurred vision. The risk information provided here is not comprehensive. To learn more, talk to your healthcare provider.

Go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program, or call 1-800-FDA-1088.

Approved Uses

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are used with the KXL® System in corneal cross-linking to treat eyes in which the cornea, the clear dome shaped surface that covers the front of the eye, has been weakened from the progression of the disease keratoconus or following refractive surgery, a method for correcting or improving your vision.

Tell your healthcare provider if you are pregnant or plan to become pregnant.